Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-75,595
Closed -$2.25M 4965
2025
Q2
$2.25M Sell
75,595
-24,966
-25% -$719K ﹤0.01% 2017
2025
Q1
$3.07M Sell
100,561
-61,505
-38% -$2.07M ﹤0.01% 1765
2024
Q4
$6.42M Buy
162,066
+98,489
+155% +$3.83M 0.01% 1447
2024
Q3
$2.47M Buy
63,577
+50,702
+394% +$2.05M ﹤0.01% 1923
2024
Q2
$541K Buy
12,875
+2,920
+29% +$99.6K ﹤0.01% 3016
2024
Q1
$292K Buy
+9,955
New +$317K ﹤0.01% 3408
2023
Q4
Sell
-40,993
Closed -$1.32M 4474
2023
Q3
$1.32M Sell
40,993
-276
-0.7% -$9.38K ﹤0.01% 2124
2023
Q2
$1.29M Buy
41,269
+2,678
+7% +$61.1K ﹤0.01% 1974
2023
Q1
$879K Buy
+38,591
New +$994K ﹤0.01% 1980
2020
Q4
Sell
-7,889
Closed -$307K 3240
2020
Q3
$307K Sell
7,889
-6,501
-45% -$286K ﹤0.01% 1779
2020
Q2
$622K Buy
14,390
+887
+7% +$33.6K 0.01% 1186
2020
Q1
$450K Sell
13,503
-18,643
-58% -$673K 0.01% 1098
2019
Q4
$1.33M Sell
32,146
-16,628
-34% -$700K 0.01% 1159
2019
Q3
$2.23M Sell
48,774
-1,019
-2% -$44.4K 0.02% 805
2019
Q2
$2.15M Buy
49,793
+18,303
+58% +$773K 0.02% 803
2019
Q1
$1.37M Buy
31,490
+12,918
+70% +$658K 0.01% 937
2018
Q4
$878K Buy
18,572
+10,969
+144% +$658K 0.01% 978
2018
Q3
$568K Sell
7,603
-5,341
-41% -$368K 0.01% 1242
2018
Q2
$715K Buy
+12,944
New +$598K 0.01% 1029

Other funds holding SRDX

Squarepoint's SRDX Position: Q3 2025 in Review

Squarepoint sold out of Surmodics (SRDX) in Q3 2025, closing a stake of 75,595 shares — an estimated $2.25M sold.

Squarepoint first reported a position in SRDX in Q2 2018 and held it in 19 quarters. The position peaked at $6.42M in Q4 2024. 146 funds tracked by Wall St. Rank hold SRDX as of Q3 2025.

  • Squarepoint reported no remaining Surmodics position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 75,595 Surmodics shares in Q3 2025, an estimated $2.25M.
  • Squarepoint first reported a position in Surmodics in Q2 2018 and held it in 19 quarters.
  • Squarepoint's Surmodics position peaked at $6.42M in Q4 2024.
  • 146 funds tracked by Wall St. Rank held Surmodics as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.